Welcome, Guest
Username: Password: Remember me
General
  • Page:
  • 1
  • 2

TOPIC: Bailed-out By Lorem Vascular

Bailed-out By Lorem Vascular 01 Apr 2019 07:12 #12731

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1273
  • Thank you received: 18
See Form 8-K!

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 01 Apr 2019 07:48 #12732

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2756
  • Thank you received: 199
Doesn't sound too good to me.
Buffering on the call sucks so I ended it as there was little of interest anyway other than Lorem is still around and will soon or at least some point be our supplier.

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 01 Apr 2019 08:44 #12733

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1273
  • Thank you received: 18

myownhedgefund wrote: Doesn't sound too good to me.
Buffering on the call sucks so I ended it as there was little of interest anyway other than Lorem is still around and will soon or at least some point be our supplier.


What "call"?

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 01 Apr 2019 09:28 #12734

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3291
  • Thank you received: 1110
Rodney-
Yes- as written on this board- the call was at 8.30 EST and I listened to it laying in my garden getting a tan with my headphone on. Sound was OK - not very good, but OK. Presently I am digesting- this is quite a change but Cytori is definitely alive and kicking AND in compliance with the Amendments 5 & 6 of the Oxford agreement.

That is presently ALL that counts. No more uncertainty of going concern as far as I am concerned. If you get "bailed out" by a Company that has sued you left, right and center- you must have done something well.....:grin: :grin:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Bailed-out By Lorem Vascular 01 Apr 2019 10:14 #12735

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1273
  • Thank you received: 18

fas wrote: Rodney-
Yes- as written on this board- the call was at 8.30 EST and I listened to it laying in my garden getting a tan with my headphone on. Sound was OK - not very good, but OK. Presently I am digesting- this is quite a change but Cytori is definitely alive and kicking AND in compliance with the Amendments 5 & 6 of the Oxford agreement.

That is presently ALL that counts. No more uncertainty of going concern as far as I am concerned. If you get "bailed out" by a Company that has sued you left, right and center- you must have done something well.....:grin: :grin:

/

I certainly agree with your last sentence - however, for some reason, I thought the call was at 5:30 pm today - what post are you referring to which indicates 8:30 am?

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 01 Apr 2019 10:38 #12738

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3291
  • Thank you received: 1110
Here

second post

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Bailed-out By Lorem Vascular 01 Apr 2019 11:08 #12739

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 872
  • Thank you received: 148
$4,000,000 for ALL Cell Therapy assets and intellectual property (outside of Japan and BARDA) and a portion of that was a receivable on the UK subs books!!? Amazing destruction of value. I wonder how the simple RECELL system, already approved for burns by FDA in U.S. with BARDA financing, will affect the Cytori burn program. There is a difference, in that Cytori tested pre-clinically on irradiated animals. However, that testing cannot be done on humans. I'm betting that if it works for Cytori technology, it will work for Avita's regenerative medicine technology.

Cytori is no longer a stem cell company. The dream has now passed yet the balance sheet will still need financing in 2019.

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 01 Apr 2019 11:13 #12740

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1273
  • Thank you received: 18

fas wrote: Here

second post


Interesting that the earnings 8-K filed today indicates a CC at 5:30ET?????

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 01 Apr 2019 13:32 #12741

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2756
  • Thank you received: 199
WST
>>>and a portion of that was a receivable on the UK subs books!!?<<<

That part is very interesting and something I missed on my quick skim until I got frustrated with the call quality and closed everything out but may answer something I did catch that perhaps I blew off as possible Cytori sloppiness too soon.
IN the 8k filed about the Lorem deal there is a link for exhibit 2.1
If one scrolls down through the terms and definitions to page 9, one gets to purchase price $3,000,000.
Interesting conflict ???????????
Note how sloppy that entire document is....did they not want anyone to bother to read it or was there simply a document transfer issue ?
secfilings.nasdaq.com/filingFrameset.asp?FilingID=13333345&RcvdDate=4/1/2019&CoName=CYTORI%20THERAPEUTICS%2C%20INC.&FormType=8-K&View=html

RS
The GlobalNewswire release on Yahoo had the correct time.
Replay should be avail. now or wait for the transcript tomorrow.

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 01 Apr 2019 14:16 #12742

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 872
  • Thank you received: 148
Hedge,

How embarrassing. $3,000,000 back after spending over $400,000,000 in total net spending since inception? Surprised to see Lorem Vascular back in the picture picking up the pieces. Salaries live on!!!!

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 01 Apr 2019 14:32 #12743

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2756
  • Thank you received: 199
I have posted my opinion here in the past that the cell business had little value...but I wonder if Mr Lim's final revenge is own all of this in the end.

Curious what the new burn rate will be after the deal closes.
Anyone hear if it was addressed on todays call ?

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 01 Apr 2019 15:35 #12744

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 872
  • Thank you received: 148
Hedge,

I think we were both in agreement that the cell business had limited value and boy was it limited. Lin's 100% of nothing is still worth nothing. Not even the baldness deal got anywhere. Now competing in oncology? I don't think so.

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 03 Apr 2019 05:23 #12756

  • rongside
  • rongside's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 377
  • Thank you received: 196
WST, Cytori has long ceased to be a stem cell company. That happened the moment they bought Azaya. Any work being carried out now in the regenerative field is being carried out by 3rd parties. BARDA is paying for burn treament trials and conceivably there is value there, but it will take a long time to realize it, if ever, especially with this management.

I do not believe that the treament of burns with Avita negates any merit in using ADRC. All the proof todate shows that ADRC do have a positive impact on burn wound healing. The decision to use the systemic application of SVF was no doubt influenced by the ease of use and effectiveness of Avita's spray on treatment. The SVF has a different method of action that works deeper within the wound bed and not on its surface. It is in my opinion complimentary to Avita. That is why BARDA is continuing to fund it.

Lim is not stupid. He sees value because he now controls his destiny and is not dependent on CYTX management. He sold his shares earl when he realised how incompetent Hedrick e al were. He had however bought a place at the table and was the owner of righs to huge markets. Lorem will be a major beneficiary if BARDA and the other trials work. Avita spray is unlikely to work on scleroderma, SUI or osteonecrosis, SVF will and then Lim will be laughing..

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 03 Apr 2019 07:19 #12758

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1273
  • Thank you received: 18

rongside wrote: WST, Cytori has long ceased to be a stem cell company. That happened the moment they bought Azaya. Any work being carried out now in the regenerative field is being carried out by 3rd parties. BARDA is paying for burn treament trials and conceivably there is value there, but it will take a long time to realize it, if ever, especially with this management.

I do not believe that the treament of burns with Avita negates any merit in using ADRC. All the proof todate shows that ADRC do have a positive impact on burn wound healing. The decision to use the systemic application of SVF was no doubt influenced by the ease of use and effectiveness of Avita's spray on treatment. The SVF has a different method of action that works deeper within the wound bed and not on its surface. It is in my opinion complimentary to Avita. That is why BARDA is continuing to fund it.

Lim is not stupid. He sees value because he now controls his destiny and is not dependent on CYTX management. He sold his shares earl when he realised how incompetent Hedrick e al were. He had however bought a place at the table and was the owner of righs to huge markets. Lorem will be a major beneficiary if BARDA and the other trials work. Avita spray is unlikely to work on scleroderma, SUI or osteonecrosis, SVF will and then Lim will be laughing..

/

If Lim is so smart, how did he get raked over the coals so badly by Calhoun 5+ years ago - I recall $24 million or so for stock plus worthless territories - even now, Lim still does not have Japan (the largest market currently for stem cell therapy)!

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 03 Apr 2019 14:50 #12760

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 872
  • Thank you received: 148
Don't think the treatments are complementary since the pre-clinical work by Athersys involved skin grafts. I suspect that Avita's RECELL will likely make Cytori's burn treatment obsolete, unless of course it has a better outcome with radiation burns which I doubt. Meanwhile, Avita shares hitting new highs as it presents at 3 day burn conference in Las Vegas,


"In the study described in this publication, Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were delivered by intravenous injection in a porcine model of mixed full-and partial thickness burn injury covering approximately 20% of total body surface area in which full thickness burns were treated with a meshed autologous split-thickness skin graft. All animals received skin grafting procedures, burn dressings, and other supportive care commonly used in burn centers around the USA.

No serious adverse events related to ADRC infusion were noted in any of the animals. Delivery of ADRCs appeared to be safe with none of the systemic safety parameters worsened compared to the control group. Importantly, skin graft healing was significantly faster in ADRC-treated animals such that five days after treatment wounds in animals treated with ADRCs were 27.1±11.8% epithelialized compared to only 1.1±1.1% in control animals (p<0.05). Skin barrier function (ability to prevent water loss) was 20-fold greater in ADRC-treated wounds than in controls on Day 9 after treatment (32.8±6.3 vs. 157.8±57.3 g/m2/h, respectively; p=0.01). Skin biological elasticity was also significantly greater in ADRCs-treated animals compared to those treated with LR (0.50±0.1 vs. 0.44± 0.02, respectively; p=0.017). Similar improvement in healing was also evident in donor sites (epithelialization 52.8% vs. 33.1% on Day 5 post-treatment) and partial thickness burn (epithelialization 81.8% vs. 59.8% on Day 18 post-treatment)."

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 03 Apr 2019 22:04 #12762

  • rongside
  • rongside's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 377
  • Thank you received: 196
WST, from the excerpts you posted relating to the porcine model one would assume that the treament would appear to be effective.
You will recall that we also have a plethora of adhoc human trial data that shows effectiveness in a variety of wound trials.
That the cellular make up of the SVF is different to that of Avita's skin cell suspension would argue for a different ie. complimentary method of action.
By injecting the SVF into the patient they will be given a systemic treatment as opposed to the topical Recell spray. Knockouts in boxing usually are the product of solid combinations. :winky:

This warrants further trials and does not necessarily mean that given Recell's effectiveness that the Celution SVF is useless. I believe that SVF will be proven to be of great value in recreating the dermis which is very important in not only burn patients but also those sufferiing from serious trauma. If anything it may well prove to accelerate the effectiveness of Recell.

As you know Recell is being trialled for not only burns but also a wide range of wounds, eg. trauma, venous leg ulcers, diabetic foot ulcers and pressure sores all of which are huge markets. I believe that SVF will complement Recell in effectively and optimally treating these, and other conditions. Both are immediately available at the bedside and autologous (ie. cheap). :vegas:

My question, if this is proven to be true, is $4m a fair price for the whole world ex Japan and USA ??????????
My second question, if true to what exent does anyone believe that this management will not give away the rights to the USA and Japan for a pittance. ???????
My third question, does CYTX have exclusive rights in the USA via the BARDA trial for burn treatment only, or also any other indications that stem from the SVF method of action as determined via the BARDA trials (ie wound treament). Is this right exclusive to Cytori or does Lorem also have rights. How are patent ownership issues resolved ......... who owns what and who licenses what from whom ????????
How did OXFORD accept the sale/transfer of Cytori's IP portfolio ??????? What has been transferred ??????

The lack of transparency on the part of management is truly sickening. :puke:

As an aside do you have a price target for Avita ....... I am long, but not as much as I would have liked given my exposure to CYTX.
The following user(s) said Thank You: b767cpt

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 04 Apr 2019 07:09 #12763

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1273
  • Thank you received: 18

rongside wrote: WST, from the excerpts you posted relating to the porcine model one would assume that the treament would appear to be effective.
You will recall that we also have a plethora of adhoc human trial data that shows effectiveness in a variety of wound trials.
That the cellular make up of the SVF is different to that of Avita's skin cell suspension would argue for a different ie. complimentary method of action.
By injecting the SVF into the patient they will be given a systemic treatment as opposed to the topical Recell spray. Knockouts in boxing usually are the product of solid combinations. :winky:

This warrants further trials and does not necessarily mean that given Recell's effectiveness that the Celution SVF is useless. I believe that SVF will be proven to be of great value in recreating the dermis which is very important in not only burn patients but also those sufferiing from serious trauma. If anything it may well prove to accelerate the effectiveness of Recell.

As you know Recell is being trialled for not only burns but also a wide range of wounds, eg. trauma, venous leg ulcers, diabetic foot ulcers and pressure sores all of which are huge markets. I believe that SVF will complement Recell in effectively and optimally treating these, and other conditions. Both are immediately available at the bedside and autologous (ie. cheap). :vegas:

My question, if this is proven to be true, is $4m a fair price for the whole world ex Japan and USA ??????????
My second question, if true to what exent does anyone believe that this management will not give away the rights to the USA and Japan for a pittance. ???????
My third question, does CYTX have exclusive rights in the USA via the BARDA trial for burn treatment only, or also any other indications that stem from the SVF method of action as determined via the BARDA trials (ie wound treament). Is this right exclusive to Cytori or does Lorem also have rights. How are patent ownership issues resolved ......... who owns what and who licenses what from whom ????????
How did OXFORD accept the sale/transfer of Cytori's IP portfolio ??????? What has been transferred ??????

The lack of transparency on the part of management is truly sickening. :puke:

As an aside do you have a price target for Avita ....... I am long, but not as much as I would have liked given my exposure to CYTX.


As I read the 8-K, the Celll Therapy business in the US was part of the Lorem deal except for BARDA.

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 04 Apr 2019 10:42 #12764

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 872
  • Thank you received: 148
Rongside,

I don't see SVF being used for burns systematically now that RECELL is FDA approved and works very well. Burn centers won't be inclined to do liposuctions when they are used to doing skin grafts. Just doesn't make sense anymore now that a such a simple and cheap disposable kit has FDA approval and IT WORKS. As far as a price target for AVITA, I wouldn't be surprised to see it at $10 this year if sales ramp up as I think they will. Right now the market cap has moved up over $400,000,000 but as you say, it has many potential markets beyond burn. You didn't mention cosmetic face lifts and Vitiligo. Also, a partner just submitted to PMDA for approval in Japan and they DON"T even need to run a clinical trial. Shares aren't even trading on a NASDAQ yet and many brokers can't buy. This is going to get even more interesting. IMHO. Having said that, all investors, as always, should do their own DD.

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 06 Apr 2019 17:34 #12771

  • rongside
  • rongside's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 377
  • Thank you received: 196
WST et al, this link provides a very good analysis of the use of stem cells in the treatment of burns. The section about Adipose stem cells is particularly interesting. I believe it makes a very good case for the complimentary nature of the therapeuic effect to that of AVITA.

academic.oup.com/jbcr/article/39/2/175/4796741

I remain very optimistic about the utility and efficacy of ADRC. Obviously that does not apply for CYTX management, but just in case, I have the following questions.

QUESTION : If CYTX retains the rights to the US market for the BARDA related trial in burns does this pertain strictly to burns or does it also relate to the method of action and therefore possibly cover a broader range of wounds..... venous leg ulcers, diabetic foot ulcers, pressure sores, trauma/degloving, etc.

QUESTION : Has CYTX in transferring the IP made any provision for license fees from Lorem Vascular to CYTX contingent on global sales ?

QUESTION : Any ideas on what is covered in the CYTX license that is to be granted by Lorem? Is management required to disclose it to us if we ask for it. ???

The sales aggreement that has been downloaded is set out (spacing) in such a way as to be almost impossible to read ........... was that intentional ????

Thanks for your estimate concerning AVITA. I believe the $10 target this year is very feasible. Once it transfers to the regular NASDAQ board it will become accessible to a much larger group of individual/institutional investors. As the market cap rises it will likely force biotech/pharma mutual funds and ETF to include it in their portfolio.

I wouid also note that AVITA has CE mark approval for approval. It did not get not get traction in the past because UK's NICE was not provided with financial cost/benefit analysis ......... hopefully the US data will go a long way in providing the necessary proof that NICE, and by extension the rest of european regulators are looking for.

www.avitamedical.com/uploads/pdf/AVITA-Press-Release-ABA-Cost-Donor-Site-and-Large-TBSA-Data-5-April-2019.pdf

Please Log in or Create an account to join the conversation.

Bailed-out By Lorem Vascular 07 Apr 2019 22:14 #12778

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 872
  • Thank you received: 148
AVITA Medical Announces Presentation at ABA Meeting Highlighting Results of Study Using RECELL® System to Treat Third-Degree Burns in Pediatric Patients
Professor Fiona Wood, co-inventor of the RECELL System, described her experience treating more than 3,500 patients using RECELL and resulting benefits including reduced time to healing and decreased length of hospitalization
The publication of the RECELL System pivotal trial in the treatment of second-degree burns was selected as a top journal publication for 2018

Valencia, Calif., USA, and Melbourne, Australia, 8 April 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) a global regenerative medicine company, announced that interim results describing clinical outcomes for pediatric patients treated using the RECELL® System were presented at the American Burn Association (ABA) 51st Annual Meeting in Las Vegas by Jeffrey Carter, MD, FACS University Medical Center New Orleans Burn Center and LSU Health New Orleans School of Medicine. Patients enrolled in the Investigational Device Exemption (IDE) Compassionate Use and Continued Access studies had mixed-depth and full-thickness (third-degree) burns and were treated with the combination of Spray-On Skin™ Cells prepared using the RECELL system and widely meshed autografts. Patients in the studies experienced excellent healing outcomes, with 98% of wounds healed four weeks after treatment. Dr. Carter’s presentation describing the treatment of pediatric patients was selected as a “Best of the Best Abstract” out of more than 500 abstract submissions to the ABA meeting.

Another one of the ten presentations related to the RECELL System at the ABA meeting was a long-term review of patient outcomes by the co-inventor of the technology, Professor Fiona Wood, AM, Burns Service of Western Australia, Fiona Stanley and Perth Children's Hospitals. Professor Wood described her experience treating more than 3,500 patients with burns and other cutaneous injuries. In addition, the 2018 publication of the RECELL System pivotal trial in second-degree burns in the Journal of Burn Care & Research was recognized during the “The Year in Review: The Top Journal Publications” session of the ABA meeting.

The RECELL System uses a small amount of a patient’s own skin to prepare Spray-On Skin Cells at the point of care in as little as 30 minutes, providing a new way to treat thermal burns. The RECELL System was approved by the U.S. Food and Drug Administration (FDA) in September 2018 for the treatment of acute thermal burns in patients 18 years and older. The pediatric presentation includes a class of patients that fall outside of the currently approved U.S. product labeling. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device ( recellsystem.com/ ) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

Best of the Best Abstract – Pediatric Burn Care
Dr. Carter presented data showing that 98% of mixed-depth/full-thickness burn Injuries in pediatric patients treated using Spray-On Skin Cells in combination with widely spaced meshed autografts were healed within four weeks of treatment. The presentation titled “Evaluation of a Pediatric Population Treated for Burn Injuries Using an Autologous Skin Cell Suspension: Interim Analysis” described the interim outcomes for 23 pediatric patients with a median age of 6.7 years old (ranging from 0.8 to 16.0) treated under FDA-IDE approved Compassionate Use and Continued Access programs. In patients with extensive burn injuries, lack of available donor skin is a major limitation achieving permanent closure, and the longer a wound remains open the more susceptible a patient is to infection. In the U.S., one-third of burn injuries occur in children, and the availability of donor skin for traditional meshed autografts is even more limited in pediatric patients with extensive injuries. The use of the RECELL System, a donor skin sparing technology that enables rapid definitive closure of burn wounds, has the potential to improve patient outcomes.

In this study of pediatric patients which included those with life-threatening thermal burn injuries, Spray-On Skin Cells prepared using the RECELL System were applied in combination with widely meshed split-thickness autografts to achieve definitive closure using minimal donor skin. A total of 107 burn injuries were treated in the study, and 98% achieved definitive healing within four weeks of treatment. Importantly, for patients with greater than 50% total body surface area (TBSA) burns, treatment with the combination of Spray-On Skin Cells and widely meshed split-thickness autografts achieved the same high rate of healing at week four as patients with smaller burns (burns equal to or less than 50% TBSA) treated with the same combination. In addition, in the study the donor sites on all patients were treated with Spray-On Skin Cells, and 62.5% of the donor sites were healed within a week of treatment, and 100% were completely healed within two weeks of treatment.

“This interim analysis supports the use of the RECELL System as a viable option for treatment in these deeper burn injuries in pediatric patients,” said Jeffrey Carter, MD, FACS University Medical Center New Orleans Burn Center and LSU Health New Orleans School of Medicine. “In this vulnerable patient population, we observed excellent clinical outcomes with 98% of wounds healing within four weeks of treatment, and with the majority of burn sites having cosmetic outcomes rated as satisfactory or equivalent compared to uninjured skin. The early healing of donor sites contributed to a decrease between harvest times for patients with limited donor skin availability.”

Co-Inventor of the RECELL System Describes More than Ten years of Experience with the RECELL System
Professor Wood described her long-term experience treating more than 3,500 patients using the RECELL System in a presentation titled “10 years of clinical experience using point of care non cultured autologous skin cell suspension harvested using the RECELL System.” Professor Wood, the co-inventor of the technology forming the basis for the RECELL System, provided an analysis of the long-term impact of the integration of the RECELL System as the standard of care in a health system providing burn care to a population of 2.6 million in Western Australia. For more than a decade the RECELL System was used in the treatment of more than 3,500 patients, 90% of which had acute burn injuries, 9% were treated for scar revision, and 1% had other wounds. More than 700 of these patients were pediatric patients, with approximately 50% suffering scald injuries.

“Our use of cell-based therapies which ultimately evolved into the RECELL System was driven by our desire to reduce the time to healing and improve the outcomes for our burn patients. The quality of life must be worth the pain of survival,“ said Professor Fiona Wood, AM, Burns Service of Western Australia, Fiona Stanley and Perth Children's Hospitals. “Treatment using the RECELL System was associated with a reduction in the number of surgical procedures, earlier intervention, and reduction in time to healing and length of stay. The RECELL System facilitated early intervention and wound healing as a solo treatment in partial-thickness injuries, and in combination with traditional techniques in deeper injuries with limited donor sites. Using a cumulative outcome index, intervention within one week of injury was associated with significantly improved outcome at three months which was maintained at one-year post injury.”

# # #

ABOUT AVITA MEDICAL LIMITED
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing Spray-On Skin™ Cells, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device ( avitamedical.com ) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

Funding and technical support for the development of the RECELL System is provided by the Biomedical Advanced Research and Development Authority (BARDA), under the Assistant Secretary for Preparedness and Response, within the U.S. Department of Health and Human Services, under ongoing USG Contract No. HHSO100201500028C. Programs funded under the BARDA contract include two randomized, controlled pivotal clinical trials, the Compassionate Use and Continued Access programs, development of the health economic model demonstrating the cost savings associated with the RECELL System, and two randomized, controlled clinical trials in pediatric burn patients.

In international markets, AVITA Medical’s products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, acute wounds, scars and vitiligo. The RECELL System is TGA-registered in Australia and CFDA-cleared in China.

To learn more, visit www.avitamedical.com .

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

U.S. Media
Sam Brown, Inc.
Christy Curran
Phone +1-615.414.8668
This email address is being protected from spambots. You need JavaScript enabled to view it.

O.U.S Media
Monsoon Communications
Sarah Kemter
Phone +61 (0)3 9620 3333
Mobile +61 (0)407 162 530
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
This email address is being protected from spambots. You need JavaScript enabled to view it.

AVITA Medical Ltd
Dale A. Sander
Chief Financial Officer
Phone +1-661-367-9178
This email address is being protected from spambots. You need JavaScript enabled to view it.





Copyright © 2019 AVITA Medical, All rights reserved.


Our mailing address is:
28159 Avenue Stanford, Suite 220
Valencia, CA 91355

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
  • 2
Time to create page: 0.162 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites